CD20 in large B-cell lymphoma
2 EU-approved indications in large B-cell lymphoma need a CD20 result: rituximab (any line) and rituximab (1st line, advanced).
Subtype
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| CD20-positive2 | ||||
MabThera | + chemotherapy | 1L advanced | DLBCL only; Children and adolescents only; Aged 6 months to less than 18 years old | |
MabThera | + CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) | Any line | DLBCL only | |
13 approvals for LBCL/DLBCL need no biomarker and apply whatever the result. All approvals for LBCL/DLBCL
See also
Label wording2
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Rituximab (MabThera)
MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
- Rituximab (MabThera)
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).